Intercept Pharmaceuticals (ICPT) PT Lowered to $200 at Oppenheimer, Keeps 'Outperform'

October 24, 2016 6:17 AM EDT
Get Alerts ICPT Hot Sheet
Price: $113.50 -1.99%

Rating Summary:
    17 Buy, 3 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 34 | New: 34
Trade ICPT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Oppenheimer analyst Jay Olson lowered his price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $200.00 (from $250.00) but maintained an Outperform rating.

Olson commented, "We refresh our Outperform rating on ICPT as we expect OCA to become a foundational therapy for the treatment of NASH either alone or in combination with other eventual treatments. We forecast ~$5B peak sales of OCA for NASH with a 64% probability of success. Meanwhile the PBC launch is on track with our expectations to reach $500M in peak annual sales. Our bullish stance on ICPT is based on our anticipation of PBC sales ramp and increased clarity around OCA's potential in NASH."

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $137.41 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Add Your Comment